Bionomics Limited

Lucratividade por seis meses: -0.5952%
Rendimento de dividendos: 0%
Setor: Healthcare

5.01 $

0 $ 0%
0.2429 $
8.31 $

Min./max. por um ano

Cronograma de promoção Bionomics Limited

Os principais parâmetros

A moeda do relatório
aud
Indústria
Biotechnology
Isin
US09063M2052
Moeda
usd
Setor
Health Care
Site
Tempo de IPO
2021-12-16

Nota

Subestimação
Nome Significado Nota
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
Eficiência
Nome Significado Nota
ROA -66284.99 0
ROE -117366.73 0
ROIC 0 0
Dividendos
Nome Significado Nota
Rendimento de dividendos 0 0
DSI 0 0
O crescimento médio de dividendos 0 0
Obrigação
Nome Significado Nota
Debt/EBITDA -0.0277 10
Debt/Ratio 0.0099 10
Debt/Equity 0.5821 9
Pulso de crescimento
Nome Significado Nota
Receita, bilhão, % -98.5 0
Ebitda, % 260.68 10
EPS, % 72123839.39 10

Preços

Preço Min. Máx. Mudar Mudanças na indústria Mudanças no índice
Ontem 5.01 $ 0 $ 0 $ 0 % 0 % 0 %
Semana 5.01 $ 0 $ 0 $ 0 % 0 % 0 %
Mês 5.01 $ 0 $ 0 $ 0 % 0 % 0 %
3 meses 5.01 $ 5.01 $ 5.01 $ 0 % 0 % 0 %
Seis meses 5.04 $ 4.88 $ 5.27 $ -0.5952 % 0 % 0 %
Ano 8.27 $ 0.2429 $ 8.31 $ -39.4 % 0 % 0 %
3 anos 7.7 $ 0.2429 $ 10.09 $ -34.94 % 0 % 0 %
5 anos 0.2429 $ 0.2429 $ 14.73 $ +2 062.58 % 0 % 0 %
10 anos 0.2429 $ 0.2429 $ 14.73 $ +2 062.58 % 0 % 0 %
No acumulado do ano 3.4 $ 2.93 $ 5.41 $ +47.35 % 0 % 0 %

Proprietários básicos

Empresas semelhantes



A administração da empresa

Supervisor Cargo Pagamento Ano de nascimento
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 anos)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 anos)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 anos)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 anos)

Informações sobre a empresa

Endereço: Australia, Eastwood, 200 Greenhill Road - Abrir no google cards, Abra os cartões yandex
Site: https://www.bionomics.com.au

Sobre a empresa Bionomics Limited

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.